News

Chemo Group subsidiary mAbxience is a biopharmaceutical firm specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.

Currently, the company is enrolling patients in an open-label multicenter Phase I/II trial, which is designed to evaluate the safety, pharmacokinetics and efficacy of GMI-1271 in combination with

ATL1103 is designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-1 (IGF-1) in the blood and is a potential treatment

Currently, AYX1 is being developed for reduction of acute post-surgical pain and prevention of the transition to persistent or chronic pain with a single administration at the time

SMC has issued its final advice, following a Health Technology Appraisal accepting linagliptin as an additional treatment option for these patients in combination with insulin with or without

The company’s latest report* states that while this growth will be primarily driven by the potential introduction of four late-stage pipeline agents, consisting of reformulations of existing therapies

Both the parties will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators to treat immunological diseases including lupus, Sjögren’s Syndrome, inflammatory bowel disease and

The summary will be presented today at 10:15 a.m. EDT at the 4th Joint International Spinal Cord Society (ISCoS) and American Spinal Injury Association (ASIA) meeting being held

The Company’s legal counsel, Ferrere Abogados of Montevideo, Uruguay, represented the Company throughout the licensing process. The Company’s license is provisional and subject to the Company submitting additional